Alpha Tau Medical Ltd. has announced that it will host a conference call to discuss new interim results from its REGAIN clinical trial, which focuses on treating recurrent glioblastoma using its innovative Alpha DaRT therapy. This call is scheduled for November 16, 2026, following the presentation of results at the Society for Neuro-Oncology conference.

The REGAIN trial is a multicenter study exploring the use of Alpha DaRT in patients with recurrent glioblastoma, a particularly aggressive form of brain cancer. The significance of this call lies in the potential impact of the findings on treatment protocols and patient outcomes in oncology.

Background

Alpha Tau Medical Ltd. is an Israeli oncology therapeutics company, focused on the research and development of the Alpha DaRT technology for treating solid tumors. The company operates under the SIC code 3841, which pertains to Surgical & Medical Instruments & Apparatus. Alpha Tau is traded on Nasdaq under the tickers DRTS and DRTSW. Recent filings include several 6-K forms, with the latest filed on November 12, 2026.

What the Filing Says

The filing states, "Alpha Tau to Host Investor Call to Review New Data from the Alpha DaRT® Recurrent Glioblastoma REGAIN Trial." This call will feature key personnel, including CEO Uzi Sofer and principal investigator Dr. Joshua Palmer.

Impact

This announcement may affect patients with recurrent glioblastoma, healthcare providers, and investors interested in innovative cancer therapies. The REGAIN trial's results could influence treatment options and clinical practices within the oncology community.

What's Next

The investor call on November 16, 2026, will provide further insights into the trial's findings and their implications for future treatment strategies. Additional information about the trial can be found on ClinicalTrials.gov.